PE20170294A1 - Inhibidores de aldosterona sintasa - Google Patents

Inhibidores de aldosterona sintasa

Info

Publication number
PE20170294A1
PE20170294A1 PE2017000086A PE2017000086A PE20170294A1 PE 20170294 A1 PE20170294 A1 PE 20170294A1 PE 2017000086 A PE2017000086 A PE 2017000086A PE 2017000086 A PE2017000086 A PE 2017000086A PE 20170294 A1 PE20170294 A1 PE 20170294A1
Authority
PE
Peru
Prior art keywords
aldosterone synthase
synthase inhibitors
pyrano
difluorophenyl
imidazol
Prior art date
Application number
PE2017000086A
Other languages
English (en)
Inventor
Jennifer Burke
Derek Cogan
John Lord
Daniel Richard Marshall
Bryan P Mckibben
Maolin Yu
Yunlong Zhang
Matthew A Cerny
Lee Fader
Kosea S Frederick
Simon Surprenant
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20170294A1 publication Critical patent/PE20170294A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Se refiere a un compuesto de formula I, donde: Cy es un sistema de anillos monociclicos o biciclicos tales como C3-C10cicloalquilo, heterociclilo, entre otros; R1 y R2 son H, C1-C3-alquilo, entre otros o R1 y R2 forman un C3-C6cicloalquilo o C3-C6-heterociclilo. Son compuestos preferidos: N-{[3-(3,4-difluorofenil)-6-metil-4-oxo-3H,4H,6H,7H-pirano[3,4-d]imidazol-6-il]metil}carbamato de ter-butilo; 3-(3,4-difluorofenil)-6,6-dimetil-3H,4H,6H,7H-pirano[3,4-d]imidazol-4-ona; entre otros. Tambien se refiere a una composicion y un metodo. Dichos compuestos inhiben la aldosterona sintasa siendo utiles en el tratamiento de nefropatia diabetica, glomerulosclerosis, entre otras
PE2017000086A 2014-07-24 2015-07-23 Inhibidores de aldosterona sintasa PE20170294A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028556P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
PE20170294A1 true PE20170294A1 (es) 2017-04-12

Family

ID=53761616

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000086A PE20170294A1 (es) 2014-07-24 2015-07-23 Inhibidores de aldosterona sintasa

Country Status (34)

Country Link
US (1) US9334285B2 (es)
EP (1) EP3172212B1 (es)
JP (1) JP6250862B2 (es)
KR (1) KR102378648B1 (es)
CN (1) CN106488921B (es)
AP (1) AP2016009616A0 (es)
AR (1) AR101290A1 (es)
AU (1) AU2015292632B2 (es)
BR (1) BR112017000584B1 (es)
CA (1) CA2956118C (es)
CL (1) CL2017000040A1 (es)
CO (1) CO2017000443A2 (es)
CY (1) CY1121063T1 (es)
DK (1) DK3172212T3 (es)
EA (1) EA031105B1 (es)
ES (1) ES2684050T3 (es)
HR (1) HRP20181441T1 (es)
HU (1) HUE039981T2 (es)
IL (1) IL249665B (es)
LT (1) LT3172212T (es)
MX (1) MX368093B (es)
MY (1) MY191352A (es)
NZ (1) NZ727188A (es)
PE (1) PE20170294A1 (es)
PH (1) PH12017500089B1 (es)
PL (1) PL3172212T3 (es)
PT (1) PT3172212T (es)
RS (1) RS57570B1 (es)
SG (1) SG11201700595RA (es)
SI (1) SI3172212T1 (es)
TW (1) TWI600658B (es)
UA (1) UA118801C2 (es)
UY (1) UY36228A (es)
WO (1) WO2016014736A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX369025B (es) * 2014-10-15 2019-10-25 Boehringer Ingelheim Int Inhibidores de aldosterona sintasa.
WO2016089800A1 (en) * 2014-12-02 2016-06-09 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
US10858342B2 (en) 2016-06-28 2020-12-08 Boehringer Ingelheim International Gmbh Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases
SG10201610038SA (en) * 2016-07-29 2017-12-28 Apple Inc Systems and methods for management of asymmetrical multi-tapped battery packs
US11958818B2 (en) 2019-05-01 2024-04-16 Boehringer Ingelheim International Gmbh (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
WO2023114170A1 (en) 2021-12-14 2023-06-22 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100703068B1 (ko) * 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
CN101410389A (zh) * 2006-03-29 2009-04-15 诺瓦提斯公司 有机化合物
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
US8912341B2 (en) * 2013-01-16 2014-12-16 Northwestern University Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones

Also Published As

Publication number Publication date
AR101290A1 (es) 2016-12-07
EA201790253A1 (ru) 2017-07-31
TW201619165A (zh) 2016-06-01
PL3172212T3 (pl) 2018-11-30
DK3172212T3 (en) 2018-08-27
JP2017521466A (ja) 2017-08-03
CN106488921A (zh) 2017-03-08
EA031105B1 (ru) 2018-11-30
AP2016009616A0 (en) 2016-12-31
WO2016014736A1 (en) 2016-01-28
BR112017000584B1 (pt) 2022-07-26
MY191352A (en) 2022-06-18
JP6250862B2 (ja) 2017-12-20
SI3172212T1 (sl) 2018-10-30
LT3172212T (lt) 2018-08-27
US20160024105A1 (en) 2016-01-28
KR20170032459A (ko) 2017-03-22
AU2015292632A1 (en) 2016-12-22
CN106488921B (zh) 2019-03-15
MX2017000929A (es) 2017-05-04
TWI600658B (zh) 2017-10-01
CO2017000443A2 (es) 2017-04-10
HUE039981T2 (hu) 2019-02-28
PH12017500089A1 (en) 2017-05-22
CY1121063T1 (el) 2019-12-11
BR112017000584A2 (pt) 2017-11-07
IL249665A0 (en) 2017-02-28
US9334285B2 (en) 2016-05-10
MX368093B (es) 2019-09-19
UY36228A (es) 2016-01-29
NZ727188A (en) 2020-01-31
CA2956118C (en) 2022-11-15
RS57570B1 (sr) 2018-10-31
PT3172212T (pt) 2018-10-08
SG11201700595RA (en) 2017-02-27
IL249665B (en) 2019-08-29
EP3172212A1 (en) 2017-05-31
KR102378648B1 (ko) 2022-03-28
CA2956118A1 (en) 2016-01-28
PH12017500089B1 (en) 2017-05-22
HRP20181441T1 (hr) 2018-11-02
CL2017000040A1 (es) 2017-07-07
ES2684050T3 (es) 2018-10-01
AU2015292632B2 (en) 2019-11-21
EP3172212B1 (en) 2018-06-13
UA118801C2 (uk) 2019-03-11

Similar Documents

Publication Publication Date Title
PE20170294A1 (es) Inhibidores de aldosterona sintasa
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
PE20181289A1 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201891501A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
BR112013021675A2 (pt) compostos de triazolopiridina como inibidores de pim cinase
ECSP13013038A (es) Inhibidores sustituidos de acetil-coa carboxilasa
PE20171099A1 (es) Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidin-2,4-diona como inhibidores de adamts para el tratamiento de osteoartritis
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
MX2018004664A (es) Antagonistas de ep4.
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)
NZ731118A (en) Dopamine d3 receptor antagonists compounds
UY36054A (es) “CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENOPIRIDOPIRAZINADIONAS NOVEDOSAS”.
PE20151718A1 (es) Compuestos piridinilpirazoloquinolina
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2